lisinopril Side Effects
Also known as: Prinivil, Zestril
Analysis of 297,692 adverse event reports submitted to the FDA from 2001 to 2025.
Total Reports
297,692
Death-Related
24,562
8.3% of reports
Hospitalizations
95,486
32.1% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 24,562 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 8,144 |
| COMPLETED SUICIDE | 2,989 |
| FATIGUE | 1,605 |
| DYSPNOEA | 1,581 |
| PAIN | 1,523 |
| PNEUMONIA | 1,511 |
| RENAL FAILURE | 1,440 |
| DIARRHOEA | 1,409 |
| VOMITING | 1,338 |
| HYPERTENSION | 1,317 |
| TOXICITY TO VARIOUS AGENTS | 1,278 |
| OFF LABEL USE | 1,260 |
| ASTHENIA | 1,259 |
| NAUSEA | 1,230 |
| DECREASED APPETITE | 1,207 |
| ACUTE KIDNEY INJURY | 1,169 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 1,158 |
| ARTHRALGIA | 1,119 |
| INJURY | 1,111 |
| CARDIAC ARREST | 1,084 |
Reactions in Hospitalization Reports
Top reactions in 95,486 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| DYSPNOEA | 6,853 |
| NAUSEA | 6,491 |
| DIARRHOEA | 5,952 |
| FATIGUE | 5,829 |
| PNEUMONIA | 5,737 |
| VOMITING | 5,604 |
| ASTHENIA | 5,266 |
| FALL | 5,228 |
| ACUTE KIDNEY INJURY | 4,895 |
| PAIN | 4,774 |
| DIZZINESS | 4,701 |
| MYOCARDIAL INFARCTION | 4,594 |
| ANGIOEDEMA | 4,301 |
| HYPOTENSION | 4,259 |
| HYPERTENSION | 4,160 |
| CHEST PAIN | 3,770 |
| CARDIAC FAILURE CONGESTIVE | 3,747 |
| HEADACHE | 3,713 |
| DEHYDRATION | 3,661 |
| CEREBROVASCULAR ACCIDENT | 3,563 |
Nearby — Related Medications
What the FAERS Data Reveals About lisinopril Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 297,692 voluntary reports linked to lisinopril and its brand equivalents (Prinivil, Zestril), spanning 2001 through 2025. Of those, 24,562 (8.3%) listed death as an outcome and 95,486 (32.1%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 52% were female and 48% male; age distribution skews toward 45-64, with 81,105 reports in that bracket. The single most reported reaction is fatigue with 19,346 submissions, followed by nausea and drug ineffective.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.